Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors-Reference-Cited by-同舟云学术

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

Published:2016-03 Issue:6 Volume:114 Page:650-658
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Vandamme Timon,Beyens Matthias,de Beeck Ken Op,Dogan Fadime,van Koetsveld Peter M,Pauwels Patrick,Mortier Geert,Vangestel Christel,de Herder Wouter,Van Camp Guy,Peeters Marc,Hofland Leo J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201625.pdf

Reference49 articles.

1. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B (2008) QuantPrime—a flexible tool for reliable high-throughput primer design for quantitative PCR. BMC Bioinformatics 9: 465.

2. Barrett P, Hobbs RC, Coates PJ, Risdon RA, Wright NA, Hall PA (1995) Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J 27 (6): 482–486.

3. Basu B, Dean E, Puglisi M, Greystroke A, Ong M, Burke WM, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson MR, Banerji U (2015a) First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. Clin Cancer Res 21 (15): 3412–3419.

4. Basu S, Ranade R, Thapa P (2015b) Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model. Nucl Med Commun 36 (8): 766–774.

5. Bendell JC, Kurkjian C, Infante JR, Bauer TM, Burris HA 3rd, Greco FA, Shih KC, Thompson DS, Lane CM, Finney LH, Jones SF (2015) A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs 33 (2): 463–471.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data;Frontiers in Endocrinology;2024-05-29

2. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice;Scientific Reports;2024-04-12

3. Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing;Scientific Reports;2023-11-10

4. Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model;Endocrine-Related Cancer;2023-11-09

5. Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay;Journal of Endocrinological Investigation;2023-10-26